Overview

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI and to Escalate Complete Response for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four to six hours during pre-study, study and end of study visits.
Phase:
Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Treatments:
Capecitabine
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin